634 related articles for article (PubMed ID: 28499554)
1. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Rodrigo-Casares V; Orrico-Sánchez A
Vaccine; 2022 Jan; 40(2):316-324. PubMed ID: 34865874
[TBL] [Abstract][Full Text] [Related]
3. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
5. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
[TBL] [Abstract][Full Text] [Related]
8. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
10. Impact of the quadrivalent HPV vaccine on disease recurrence in men exposed to HPV Infection: a randomized study.
Coskuner ER; Ozkan TA; Karakose A; Dillioglugil O; Cevik I
J Sex Med; 2014 Nov; 11(11):2785-91. PubMed ID: 25124237
[TBL] [Abstract][Full Text] [Related]
11. The incidence of genital warts in Australian women prior to the national vaccination program.
Brotherton JM; Heywood A; Heley S
Sex Health; 2009 Sep; 6(3):178-84. PubMed ID: 19653953
[TBL] [Abstract][Full Text] [Related]
12. Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis.
Denecke A; Iftner T; Iftner A; Riedle S; Ocak M; Luyten A; Üye I; Tunc K; Petry KU
BMC Infect Dis; 2021 Jul; 21(1):634. PubMed ID: 34215215
[TBL] [Abstract][Full Text] [Related]
13. HPV vaccines to prevent cervical cancer and genital warts: an update.
Dochez C; Bogers JJ; Verhelst R; Rees H
Vaccine; 2014 Mar; 32(14):1595-601. PubMed ID: 24606637
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
15. Preventing cervical cancer and genital warts - How much protection is enough for HPV vaccines?
Stanley M
J Infect; 2016 Jul; 72 Suppl():S23-8. PubMed ID: 27211079
[TBL] [Abstract][Full Text] [Related]
16. Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.
Perkins RB; Lin M; Wallington SF; Hanchate A
Sex Transm Dis; 2017 Jun; 44(6):365-370. PubMed ID: 28499288
[TBL] [Abstract][Full Text] [Related]
17. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
18. What can surveillance of genital warts tell us?
Fairley CK; Donovan B
Sex Health; 2010 Sep; 7(3):325-7. PubMed ID: 20719222
[TBL] [Abstract][Full Text] [Related]
19. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
